English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law?

Drexl, J. (2013). AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law? In J. Drexl, & N. R. Lee (Eds.), Pharmaceutical Innovation, Competition and Patent Law - a Trilateral Perspective (pp. 290-322). Cheltenham, UK; Northampton, MA: Edward Elgar.

Item is

Basic

show hide
Genre: Contribution to Collected Edition

Files

show Files

Locators

show
hide
Locator:
http://ssrn.com/abstract=2009276 (Preprint)
Description:
-
OA-Status:

Creators

show
hide
 Creators:
Drexl, Josef1, Author           
Affiliations:
1MPI for Intellectual Property and Competition Law, Max Planck Society, ou_830549              

Content

show
hide
Free keywords: patent law, competition law, medicinal law, pharmaceuticals, innovation
 Abstract: In its Pharmaceutical Sector Inquiry Report of 2009, the European Commission identified ‘defensive patent strategies’ as a potential anti-competitive abuse in the sense of Article 102 TFEU. Such strategies include in particular patent filings that may delay the market entry of generic drugs or obstruct innovation activity of other originator companies. Yet the Report refrains from a an in-depth legal analysis of such behaviour. With the objective of clarifying the legal implications of the Sector Inquiry Report, the article analyses the AstraZeneca judgment of the General Court of 2010 as a precedent for assessing the anti-competitive character of patent filings under EU competition law. Thereby, it is argued that patent law does not insulate filings against competition-law liability. Yet the judgment, which is limited to ‘static’ price competition between originator companies and generics producers, does not provide sufficient guidance for analysing harm to ‘dynamic’ competition in innovation among originator companies. In this regard, the article advocates a cautious approach, according to which a violation of EU competition law requires anti-competitive intent for which the party arguing a violation should carry the burden of proof. The article also refers to the Boehringer case, which was settled by the Commission in Summer 2011, after Boehringer agreed to give up its allegedly anti-competitive blocking patents.

Details

show
hide
Language(s): eng - English
 Dates: 2013
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Pharmaceutical Innovation, Competition and Patent Law - a Trilateral Perspective
Source Genre: Collected Edition
 Creator(s):
Drexl, Josef1, Editor           
Lee, Na Ri1, Editor           
Affiliations:
1 MPI for Intellectual Property and Competition Law, Max Planck Society, ou_830549            
Publ. Info: Cheltenham, UK; Northampton, MA : Edward Elgar
Pages: - Volume / Issue: - Sequence Number: - Start / End Page: 290 - 322 Identifier: ISBN: 978-0-85793-245-7